Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

OSE Immunotherapeutics has shared survival data behind a therapeutic vaccine’s phase 2 pancreatic cancer win as the French ...

Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if ...

The addition of relacorilant to nab-paclitaxel significantly extended survival for women with platinum-resistant ovarian ...

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, ...

Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer ...

The company is increasing its awareness campaign for cancer advocacy, including a partnership with the Chicago Cubs announced ...

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...

"New discoveries are needed to find lifesaving treatments for ovarian cancer, a cancer that tragically still has a low survival rate. Equipping leading researchers around the globe with powerful ...

Twelve-year-old Maddie Muller, in remission from ovarian cancer, walked the runway to raise awareness and support research. Diagnosed at 8 with no symptoms, she now inspires others fighting the ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...